Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn’s patients and are not inducible in murine models of colitis

Figure 1 Anti-Saccharomyces cerevisiae (A) IgG and (B) IgA antibody titers in ASCA-positive patients with Crohn’s disease expressed as a logarithmically (ln) scaled dilution unit of a highly positive control over a time-period of up to 3 years.

Figure 2 Histogram of change in ASCA IgA and IgG titers (∆IgG/A) in patients with Crohn’s disease (CD), ulcerative colitis (UC) and irritable bowel syndrome (IBS). CD patients demonstrate higher variability as compared to UC and IBS.

Figure 3 OD at 450 nm representing relative levels of polyclonal anti-Saccharomyces cerevisiae antibody (ASCA) (A) in control Balb/c mice (empty columns) or mice with DSS-induced experimental colitis (shaded columns). Basal ASCA titers were determined at the start of the experiment. During the experiment, mice received water containing 100 μg/mL or 500 μg/mL yeast solution ad libitum. (B) Balb/c mice were immunized with water or 50μg yeast mannan or ovalbumin mixed 1:1 (v:v) in GERBU adjuvant. After 2 wk, mice received a booster injection and ASCA or anti ovalbumin antibodies were determined 7 d later. ^aP<0.05.